Please login to the form below

Not currently logged in
Email:
Password:

Clovis Oncology

This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare.

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for ... That is another key element in its defence of the brand, as is

Latest news

  • Maintenance OK boosts AstraZeneca’s Lynparza in Europe Maintenance OK boosts AstraZeneca’s Lynparza in Europe

    The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for ... That is another key element in its defence of the brand, as is

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    It also gave its blessing to Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) for the treatment of relapsed or progressive ovarian cancer in patients who have already been treated with two

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib). ... Tesaro and Clovis will report fourth quarter results this week.

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    Approval beyond ovarian cancer is a big hurdle cleared for Lynparza as it tries to keep pace in the market with newer PARP inhibitor entrants Rubraca (rucaparib) from Clovis Oncology and ... Merck (known as MSD outside the US and Canada) got involved in

  • CHMP backs maintenance therapy for Tesaro's Zejula CHMP backs maintenance therapy for Tesaro's Zejula

    Swiss biotech Tesaro has picked up a CHMP recommendation for its PARP inhibitor Zejula as a maintenance therapy for ovarian cancer, upping the ante in its rivalry with AstraZeneca and Clovis ... Oncology. The EMA's advisory committee backed Zejula

More from news
Approximately 4 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Roche's Julie Warner joins Boyds Roche's Julie Warner joins Boyds

    She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics